142 related articles for article (PubMed ID: 26780070)
1. [Immunotherapy in the treatment of advanced or metastatic melanoma: nivolumab from phase I studies to approvement by European Medicines Agency].
Queirolo P; Tanda ET
Recenti Prog Med; 2015 Dec; 106(12):608-17. PubMed ID: 26780070
[TBL] [Abstract][Full Text] [Related]
2. Therapy for metastatic melanoma: the past, present, and future.
Finn L; Markovic SN; Joseph RW
BMC Med; 2012 Mar; 10():23. PubMed ID: 22385436
[TBL] [Abstract][Full Text] [Related]
3. Are patients in haemodialysis good candidates for immunotherapy treatment?
Fernandez-Diaz AB; Cunquero-Tomas AJ; Garcia-Medina A; Ferrer-Guillen B; Berrocal A
Melanoma Res; 2019 Oct; 29(5):553-555. PubMed ID: 31464825
[TBL] [Abstract][Full Text] [Related]
4. The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.
Sullivan RJ; Lorusso PM; Flaherty KT
Clin Cancer Res; 2013 Oct; 19(19):5283-91. PubMed ID: 24089441
[TBL] [Abstract][Full Text] [Related]
5. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics.
Lo JA; Fisher DE
Science; 2014 Nov; 346(6212):945-9. PubMed ID: 25414302
[TBL] [Abstract][Full Text] [Related]
6. [Targeted therapies and immunotherapies in melanoma: A temporal approach to achieve optimal responses].
Braissand N; Coste I
Med Sci (Paris); 2023 Nov; 39(11):889-892. PubMed ID: 38018935
[TBL] [Abstract][Full Text] [Related]
7. What role can LAG-3-blocking antibodies play in melanoma therapy?
Rutkowski P; Jagodzińska-Mucha P
Expert Opin Biol Ther; 2023; 23(12):1155-1158. PubMed ID: 37936502
[No Abstract] [Full Text] [Related]
8. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.
Weber J; Gibney G; Kudchadkar R; Yu B; Cheng P; Martinez AJ; Kroeger J; Richards A; McCormick L; Moberg V; Cronin H; Zhao X; Schell M; Chen YA
Cancer Immunol Res; 2016 Apr; 4(4):345-53. PubMed ID: 26873574
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
10. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I
Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.
Gandini S; Massi D; Mandalà M
Crit Rev Oncol Hematol; 2016 Apr; 100():88-98. PubMed ID: 26895815
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab for Metastatic Melanoma.
Gupta AK; Daigle D
Skin Therapy Lett; 2016 Mar; 21(2):6-9. PubMed ID: 27223114
[TBL] [Abstract][Full Text] [Related]
13. PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.
Lee J; Kefford R; Carlino M
Immunotherapy; 2016 Jun; 8(6):733-46. PubMed ID: 27197541
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer.
Keating GM
Drugs; 2016 Jun; 76(9):969-78. PubMed ID: 27189706
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
Danlos FX; Pagès C; Baroudjian B; Vercellino L; Battistella M; Mimoun M; Jebali M; Bagot M; Tazi A; Lebbé C
Chest; 2016 May; 149(5):e133-6. PubMed ID: 27157227
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.
Rajan A; Kim C; Heery CR; Guha U; Gulley JL
Hum Vaccin Immunother; 2016 Sep; 12(9):2219-31. PubMed ID: 27135835
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials.
Jin C; Zhang X; Zhao K; Xu J; Zhao M; Xu X
Onco Targets Ther; 2016; 9():1571-8. PubMed ID: 27051297
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of nivolumab in the treatment of advanced melanoma.
Asmar R; Yang J; Carvajal RD
Ther Clin Risk Manag; 2016; 12():313-25. PubMed ID: 27013881
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
20. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma.
Spain L; Higgins R; Gopalakrishnan K; Turajlic S; Gore M; Larkin J
Ann Oncol; 2016 Jun; 27(6):1135-1137. PubMed ID: 26951628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
